Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: therapeutic target + multiple sclerosis + new  Related to the article below (Last Update: 8/7/2008)

New Novo Nordisk head details Seattle plans
Seattle Post Intelligencer -
Among the indications Novo Nordisk hopes to target in Seattle are autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, ...
Shape, Not Just Size, Impacts Effectiveness Of Emerging ...
Science Daily (press release) - Aug 4, 2008
... that could lead to new and more effective methods for treating cancer and other diseases, from diabetes and multiple sclerosis to arthritis and obesity. ...
Applicability of Biomarkers Is Far-Reaching
Genetic Engineering News (press release), NY - Aug 1, 2008
The result of this work is the first biochip prototype for serum-based diagnosis and therapeutic monitoring of multiple sclerosis, according to Dr. Beator. ...
Maxygen, Inc. Q2 2008 Earnings Conference Call Transcript
Seeking Alpha, NY - Jul 31, 2008
We have a preclinical program of MAXY-4 ? it is a biosuperior CTLA4-Ig protein therapeutic. Our current target indication is rheumatoid arthritis, ...MAXY
APOSENSE(R) [18F]-ML-10 for Molecular Imaging of Apoptosis to ...
MarketWatch - Jul 23, 2008
Therapeutic applications of APOSENSE technology in pre-clinical development include anticancer therapy which uses apoptotic cells in tumors as targets for ...OTC:MLRI - OTC:CMTX
TheSubway.com: Early Market Alerts PSTI is Pick of the Day ...
Trading Markets (press release), CA - Aug 1, 2008
It is also investigating the use of these cells in stroke, multiple sclerosis, and inflammatory bowel disease, and, in conjunction with hematopoietic stem ...PSTI - C - MSFT
Merck Serono: Erbitux Phase III Clinical Study in Gastric Cancer ...
뉴스와이어, South Korea - Jul 10, 2008
Merck Serono has leading brands serving patients with cancer (Erbitux), multiple sclerosis(Rebif), infertility (Gonal-f), endocrine and cardiometabolic ...
Sanofi-aventis News
PR Newswire (press release), NY - Jul 31, 2008
Teriflunomide is a potential oral treatment for multiple sclerosis, with a targeted efficacy profile similar to interferons on relapse and progression of ...SNY
Luna Awarded NIH Grant to Apply Nanotechnology to Allergy Treatment
Small Times - Jul 23, 2008
This novel research program may offer a new therapeutic solution using fullerene compounds for treating allergies and other conditions that play a central ...LUNA
Luna Receives NIH Grant
Trading Markets (press release), CA - Jul 27, 2008
According to a release, the novel research program may offer a new therapeutic solution using fullerene compounds for treating allergies and other ...LUNA - OTC:CMTX
Source: Google News

… Macrophage Colony-stimulating Factor A New Putative Therapeutic Target in Multiple Sclerosis -
JL McQualter, R Darwiche, C Ewing, M Onuki, TW Kay … - Journal of Experimental Medicine, 2001 - Rockefeller Univ Press
... Original Article. Granulocyte Macrophage Colony-stimulating Factor: A New
Putative Therapeutic Target in Multiple Sclerosis. Jonathan ...

Interleukin-10 Therapy--Review of a New Approach -
K Asadullah, W Sterry, HD Volk - Pharmacological Reviews, 2003 - ASPET
... h. Multiple Sclerosis. ... Prospects of Interleukin-10/Interleukin-10 Receptor As a
Therapeutic Target. ... They give new insight into the immunobiology of IL-10 and ...

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection -
O Neuhaus, JJ Archelos, HP Hartung - Trends in Pharmacological Sciences, 2003 - Elsevier
... Multiple sclerosis (MS) is the most common disabling ... MS, the efficacy of several
promising new concepts is ... of MS and, hence, constitutes a therapeutic target. ...

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. -
C Bjartmar, BD Trapp - Current Opinion in Neurology, 2001 - co-neurology.com
... Recently, new insights regarding the timing and ... Neuronal dynamics in multiple sclerosis
TOP. ... Inflammation remains the major therapeutic target during RR-MS and ...

Axon pathology in neurological disease: a neglected therapeutic target -
MP Coleman, VH Perry - Trends in Neurosciences, 2002 - Elsevier
... in neurological disease: a neglected therapeutic target. ... as diverse as multiple
sclerosis, stroke, traumatic ... process could lead to new therapeutic interventions ...

Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases -
J Bousquet, R Lockey, HJ Malling, E Alvarez-Cuesta … - Annals of Allergy, Asthma and Immunology, 1998 - ingentaconnect.com
... tients, the optimal therapeutic target dose, and the degree ... These new ap- proaches
will be directed at ... dis- eases, like type I diabetes and multiple sclerosis. ...

… K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis -
C Beeton, H Wulff, J Barbaria, O Clot-Faybesse, M … - Proceedings of the National Academy of Sciences, 2001 - National Acad Sciences
... Kv1.3 channels are a therapeutic target for T ... Potassium Channel-blockers as Therapeutic
Agents to ... Home page Oral Presentations Multiple Sclerosis, September 1 ...

Interleukin 1 in the brain: biology, pathology and therapeutic target -
NJ Rothwell, GN Luheshi - Trends in Neurosciences, 2000 - Elsevier
... experimental tool and a potential therapeutic agent, it ... its consensus sequence on
a target gene promoting ... 18]), an animal model of multiple sclerosis (MS), but ...

TNFalpha as therapeutic target: new drugs, more applications -
AM Reimold? - Curr Drug Targets Inflamm Allergy, 2002 - ingentaconnect.com
... TNFa as Therapeutic Target: New Drugs, More Applications ... crucial cytokine in the
establishment and maintenance of inflammation in multiple autoimmune diseases ...

Neuropathology in multiple sclerosis: new concepts -
H Lassmann - Multiple Sclerosis, 1998 - msj.sagepub.com
... of the disease and design therapeutic strategies, which speci?cally target the diverse ...
(1996) Spinal cord atrophy and disability in multiple sclerosis. ...

Source: Google Scholar
 
 

Dendritic cells offer new therapeutic target for drugs to treat multiple sclerosis

Researchers at the Johns Hopkins Kimmel Cancer Center have found that a gene pathway linked to a deadly form of leukemia may provide a new way to treat autoimmune diseases, including multiple sclerosis.
Their tests in cell cultures and mice suggest that blocking the pathway by interfering with a blood cell growth gene, known as FLT3, targets an immune system cell often ignored in favor of T-cell targets in standard therapies.

FLT3, which controls the development of healthy blood cells, was identified as a treatment target in patients with acute myeloid leukaemia several years ago by the same Johns Hopkins investigators.
In the current work, the Hopkins team has confirmed that the gene is activated in dendritic cells, whose role is to distribute "look here" information about unwanted foreign invaders to soldiering T-cells.

" Someday, using a drug to block FLT3 gene signaling could stop dendritic cells from triggering harmful responses against a patient's own body," says Donald Small, at the Johns Hopkins Kimmel Cancer Center, whose findings appear in the Proceedings of the National Academy of Sciences ( PNAS ).
 
A characteristic of autoimmune diseases is that patients' immune T-cells mistake normal cells in the body for foreign ones.
Current therapies, such as steroids, are designed to suppress T-cell responses. But the Hopkins investigators believe that targeting dendritic cells may stop the faulty immune response at a higher "upstream" level since T-cells frequently receive their information from dendritic cells.

Testing their idea, Small and his colleague Katherine Whartenby used an experimental compound called CEP-701, already known to block actions of the growth-promoting FLT3 gene, on human dendritic cells and in mice engineered to mimic multiple sclerosis, a disease that causes T-cells to destroy the myelin protein sheath around nerves in the central nervous system.
The drug had a similar effect on dendritic cells, causing most of them to die.
In the mouse model, investigators found that more of the myelin sheath was preserved in mice treated with CEP-701 than those not treated.
 
Small cautions that massive die-off of dendritic cells poses a possible risk of immune system suppression, a condition that could leave patients vulnerable to infections or other diseases. " But our studies show that though many dendritic cells were destroyed, some still remained," he said.

Their tests also revealed that mice infected with a potent bacterium survived after treatment with CEP-701.

Source: Johns Hopkins Medical Institutions, 2005
 
Google
Web www.iconocast.com
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page